GE Introduces Discovery LS

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WAUKESHA, Wisconsin-GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

WAUKESHA, Wisconsin—GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

The Discovery LS generates high-quality PET and CT images of a patient in a single 30-minute examination. Two image data sets are registered and fused to form a single image.

The Discovery LS is currently installed for clinical use at University Hospital, Zurich, Switzerland; Johns Hopkins Medical Institutions; and Rambam Medical Center, Haifa, Israel. GE forecasts that 30 systems will be installed worldwide by the end of this year and more than 500 in the next 3 years.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content